Paolo Ghia, MD

Paolo Ghia, MD, provided insights into the significance of updated data from the final analysis of the phase 2 CAPTIVATE study in CLL/SLL.

Paolo Ghia, MD, PhD, discusses the safety considerations of fixed-duration ibrutinib plus venetoclax after retreatment in patients with CLL.

Paolo Ghia, MD, highlights the rationale for evaluating pirtobrutinib for the treatment of patients with relapsed/refractory CLL.

Paolo Ghia, MD, PhD, discusses the efficacy of fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL.

Paolo Ghia, MD, PhD, discusses the rationale for conducting an OS analysis of fixed-duration ibrutinib plus venetoclax in patients with CLL.

Paolo Ghia, MD, PhD, discusses ongoing and future directions for the investigation of fixed-duration ibrutinib/venetoclax in CLL.

Paolo Ghia, MD, PhD, discusses long-term data for fixed-duration ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses future research directions and potential roles for first-line, fixed-duration ibrutinib plus venetoclax in CLL.

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Paolo Ghia, MD, PhD, discusses long-term follow-up data from a pooled analysis evaluating the efficacy of acalabrutinib monotherapy in CLL.

Paolo Ghia, MD, PhD, full professor, discusses a biomarker subgroup analysis of the phase 3 SEQUOIA trial investigating zanubrutinib vs bendamustine plus rituximab in patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without 17p deletions.

Dr. Hill and Dr. Gia discuss treatment options for patients who progress on covalent and noncovalent BTK inhibitors.

Exploring molecular mechanisms of resistance to BTK inhibitors as well as emergent data concerning how this resistance might be overcome.

Dr. Hill and Dr. Gia share how varying risk profiles of different BTK inhibitors may impact patient outcomes, along with relevant real-world data.

An insightful analysis of head-to-head trials comparing BTK inhibitors (acalabrutinib vs ibrutinib and zanubrutinib vs ibrutinib) to guide treatment selection in CLL.

Subject-matter experts review treatment options for patients with relapsed/refractory CLL.

Brian T. Hill, MD, Ph.D., and Paulo Gia, MD explain the mechanism of action of BTK inhibitors and the rationale behind their use in chronic lymphocytic leukemia (CLL).

Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).

Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses the rationale for the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.

Paolo Ghia, MD, PhD, discusses how use the of chemotherapy is decreasing in favor of novel agents in chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, discusses updated results from the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Paolo Ghia, MD, discusses the efficacy results of the ASCEND trial, which examined the use of acalabrutinib monotherapy in patients with previously treated chronic lymphocytic leukemia.